Dutch Sustainable Food Technology Sector Eyes €17 Billion Windfall by 2040

Dutch Sustainable Food Technology Sector Eyes €17 Billion Windfall by 2040

2026-11-18 bio

Amsterdam, Thursday, 19 November 2026.
Invest-NL projects Dutch sustainable food innovation could yield €17 billion annually by 2040, provided policymakers accelerate authorization timelines that lag years behind the United States.

Unlocking Economic Scale in Agritech Innovation

The release of the “Agrifood Biotech Deep Dive” report by Dutch innovation agency Invest-NL on November 17, 2026, places the spotlight firmly on the Netherlands’ expanding agritech and biotechnology industries [1]. Rather than representing a clinical healthtech or pharmaceutical breakthrough, this development is situated directly within agrifood technology—an economic sphere focused on transforming food production systems through cellular agriculture, yeast fermentation, seed breeding, genetics, and biological agricultural inputs [1][2][6]. The core benefit of this technological transition lies in creating climate-resilient crops and sustainable food ingredients that lessen ecological pressure while building domestic industrial resilience [1][5].

The Science of Fermentation and Scale Bottlenecks

At the operational level, companies operating in this niche harness cellular agriculture and microbial organisms, using fermentation processes to cultivate high-value food inputs and alternative proteins without traditional livestock farming [1][2][6]. One key entity actively advancing this approach is Revyve, co-founded by Corjan van den Berg [1]. The company works by extracting proteins from yeast, transforming microbial biomass into functional culinary ingredients that mimic traditional proteins [1]. However, translating laboratory breakthroughs into commercial manufacturing requires heavy capital commitments, as van den Berg underscored: “The science is improving all the time. The real challenge is financing the journey to commercial scale. Investors alone cannot bear this burden. Companies also need loans, guarantees, and grants to make the transition to industrial production” [1].

Despite the clear long-term potential, market deployment faces acute regulatory lag across the continent [1][2]. European authorization protocols for biological crop protection products can drag on for eight to 10 years [1]. Concurrently, EU authorization processes for novel fermentation-derived proteins take one to three years longer than equivalent pathways in the United States [1]. This institutional drag threatens to impair the transition from scientific proof-of-concept to full-scale commercialization, prompting calls from researchers and industry leaders for clearer regulatory trajectories and testbeds [1][7].

Targeting €17 Billion by 2040 Through Strategic Intervention

The financial divergence outlined by Invest-NL illustrates the economic stakes of bridging these regulatory and financing hurdles [1][2]. Without active policy modifications, Dutch biotechnology-derived ingredient revenue is projected to languish at approximately $2.2 billion by 2040; however, proactive support could accelerate this to roughly $8.8 billion [1]. Across the broader Dutch agrifood biotechnology domain, successful industrial scaling is forecast to deliver €17 billion (equivalent to approximately $18.7 billion) in additional annual revenue by 2040, unlocking an absolute annual expansion of 9.9 billion beyond ingredients alone [1][2][5]. To realize this expansion, Invest-NL has established intermediate targets for 2030: doubling the number of agrifood biotech ventures, accelerating market arrival times threefold, and establishing five globally competitive Dutch biotech champions [2].

Bronnen


biotechnology agritech